Proof-of-concept studies reveal that the promotion of the mitochondrial metabolism by sirtuin agonists or irisin recombinant protein has remedial effects to estrogen deficiency-induced osteoporosis or biophysical disuse-mediated bone deterioration. Here, FNDC5 is linked to osteoporosis.